|Positive WB detected in||HepG2 cells, HeLa cells, rat spleen tissue, L02 cells, HEK-293 cells, NIH/3T3 cells|
|Positive IHC detected in||human liver cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:5000-1:50000|
|Immunohistochemistry (IHC)||IHC : 1:100-1:400|
|Immunofluorescence (IF)||IF : 1:50-1:200|
|Sample-dependent, check data in validation data gallery|
66373-1-Ig targets G6PD in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||G6PD fusion protein Ag21862|
|Full Name||glucose-6-phosphate dehydrogenase|
|Calculated molecular weight||59 kDa|
|Observed molecular weight||60 kDa|
|GenBank accession number||BC000337|
|Gene ID (NCBI)||2539|
|Purification Method||Protein A purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
G6PD(Glucose-6-phosphate 1-dehydrogenase) belongs to the glucose-6-phosphate dehydrogenase family. It is a housekeeping enzyme encoded in mammals by an X-linked gene. G6PD has important functions in intermediary metabolism because it catalyzes the first step in the pentose phosphate pathway and provides reductive potential in the form of NADPH.(PMID:7489710). This protein has 3 isoforms produced by alternative splicing.
High glucose-induced ubiquitination of G6PD leads to the injury of podocytes.
Progesterone Regulates Glucose Metabolism Through Glucose Transporter 1 to Promote Endometrial Receptivity.
Clin Transl Med
SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching.
Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation.